TokenPost·
Helix BioPharma Reports Fiscal 2026 Loss of C$0.04 Per Share
The loss narrowed from C$0.09 per share a year earlier. Cash reserves were C$804,000 on July 31, compared with C$65,000 a year earlier.
More news
- TokenPostTrezor Warns CryptoBilis Safe 5 Buyers of Tampering Risk
- TokenPostQuad Sets 2026 Adjusted EBITDA Forecast at $185 Million to $195 Million
- TokenPostBinance Says Employee PC Breach Was Only the First Step in Attack
- TokenPostTrezor Flags Suspected Implant in Safe 5 Sold by CryptoBilis
- TokenPostCanadian Sentenced to 25 Months in Case Tied to 185 Bitcoin (BTC) Theft
- TokenPostSaemin Ahn Sees Southeast Asia Struggling to Attract Venture Capital